Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.04 - $238.00
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.83M
Market Cap
$17.64B
Enterprise Value$26.68B
Total Cash (Recent Filing)$639.56M
Total Debt (Recent Filing)$1.10B
Price to Earnings (P/E)10.8
Beta0.69
Next Earnings
May 01, 2025EPS Estimate
3.43Last Dividend Ex-Date
Feb 02, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)11.18
Shares Outstanding146,374,940
10 Day Avg. Volume1,861,236
30 Day Avg. Volume1,825,114
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)N/A
Price to Sales (P/S)2.13
Price to Cash Flow (P/CF)6.80
P/FCF Ratio6.30
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda11.63
Forecast
1Y Price Target
$190.77Price Target Upside68.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
---
Bulls Say, Bears Say
Bulls Say
Collaborations And PartnershipsBiogen announced a collaboration with Stoke Therapeutics for the development of a treatment for Dravet syndrome, which aligns with their expertise in neuro, immunology, and rare diseases.
Product PerformanceLeqembi continues its positive trajectory especially in the USA, supporting the real-world data from the academic centers.
Regulatory DevelopmentsThe European Medicines Agency's Committee for Medicinal Products for Human Use reversed its decision and recommended Biogen/Eisai's Leqembi for Alzheimer's patients.
Bears Say
Financial PerformanceThe stock is down 4% as the midpoint of the 2025 EPS guidance is notably below consensus.
Product Portfolio ChallengesFresh pipeline cuts to BIIB113, BIIB093, BIIB101, and BIIB143 (cemdomespib), further trim down Biogen's portfolio, which was lean to start.
Revenue And Growth ChallengesRevenue erosion continues with unclear path to near-term sustained growth.
---
Ownership Overview
0.16% Insiders
32.80% Mutual Funds
22.41% Other Institutional Investors
11.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $238.00 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $17.64B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is May 01, 2025 which is in 20 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Feb 12, 2025. The company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.331 by $0.109.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen pays a Notavailable dividend of $22.225 which represents an annual dividend yield of N/A. See more information on Biogen dividends here
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.43.
How many shares outstanding does Biogen have?
Biogen has 146,374,940 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $3.44 in its last earnings report, beating expectations of $3.331. Following the earnings report the stock price went down -4.276%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
---
Biogen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$190.77 (68.26% Upside)
$190.77 (68.26% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 998.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.65%
12-Months-Change
Fundamentals
Return on Equity
10.36%
Trailing 12-Months
Asset Growth
4.49%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. is a leading biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, Biogen is dedicated to advancing science and medicine to improve patient outcomes in areas such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company's core products include a range of therapies addressing these complex conditions, making it a prominent player in the healthcare sector.
---
BIIB Company Deck
---
BIIB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Biogen's earnings call highlighted successful new product launches and operational efficiency, offsetting declines in its multiple sclerosis franchise. However, challenges persist in identifying patients for SKYCLARYS and pressure on MS revenues is expected to continue.Read More>---
BIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
---
BIIB Stock 12 Month Forecast
Average Price Target
$190.77
▲(68.26% Upside)
Technical Analysis
Best Analysts Covering BIIB
1 Year
1 Year Success Rate
11/39 ratings generated profit
1 Year Average Return
-9.93%
reiterated a buy rating 2 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 28.21% of your transactions generating a profit, with an average return of -9.93% per trade.
---